Hodgkin hastalığının standart tedavisinde rekombinant human granülosit koloni stimüle edici faktör kullanımı
| dc.contributor.author | Özkalemkaş, Fahir | |
| dc.contributor.author | Ali, Rıdvan | |
| dc.contributor.author | Karaaslan, Yusuf | |
| dc.contributor.author | Özkocaman, Vildan | |
| dc.contributor.author | Tunalı, Ahmet | |
| dc.date.accessioned | 2015-08-06T07:51:03Z | |
| dc.date.available | 2015-08-06T07:51:03Z | |
| dc.date.issued | 1998 | |
| dc.description | [Journal of Turgut Özal Medical Center 1998;5(1):24-29] | en_US |
| dc.description.abstract | The aim of this study was to evaluate the effectiveness of recombinant granulocyte colony stimulating factor (rhG-CSF) administered following cytotoxic chemotherapy in Hodgkin's disease. Total number of 26 courses of rhG-CSF were applied in 19 patients with Hodgkin's disease aged 15 to 61 (median 44) years. They received MOPP (Nitrogen Mustard, Vincritine, Procarbazine, Prednisone) chemotherapy every 28 days. rhG-CSF was given at a dose of 5^/kg daily and subcutaneously from day 2nd to 6th day 8th to 20h unless the neutrophil count exceeded 10.000/mm3, in which case rhG-CSF discontinued. The outcome was compared with 24 prognostically similar control patients treated with the same chemotherapy without rhG-CSF. Recovery of granulocyte counts above 1000/mm was significantly faster in the rhG-CSF treated group (3±0.72 days vs 7±0.81 days; p<0.001). The incidence of febrile neutropenia and empiric parenteral antibiotic use were lower in study patients (%36 vs %64 ; p<0.05). But there was no reduction in the incidence of documented infections. Full doses of chemotherapy could be given on time to 26/26 (%100) rhG-CSF patients but to only 18/24 (%75) controls (p<0.01). All patients tolerated cytokine treatment well. Our results showed that rhG-CSF has an important role in decreasing period of neutropenia maintaining chemotherapy schedule and allowing patients to receive full doses of chemotherapy on time. [Journal of Turgut Özal Medical Center 1998;5(1):24-29] | en_US |
| dc.description.abstract | The aim of this study was to evaluate the effectiveness of recombinant granulocyte colony stimulating factor (rhG-CSF) administered following cytotoxic chemotherapy in Hodgkin's disease. Total number of 26 courses of rhG-CSF were applied in 19 patients with Hodgkin's disease aged 15 to 61 (median 44) years. They received MOPP (Nitrogen Mustard, Vincritine, Procarbazine, Prednisone) chemotherapy every 28 days. rhG-CSF was given at a dose of 5^/kg daily and subcutaneously from day 2nd to 6th day 8th to 20h unless the neutrophil count exceeded 10.000/mm3, in which case rhG-CSF discontinued. The outcome was compared with 24 prognostically similar control patients treated with the same chemotherapy without rhG-CSF. Recovery of granulocyte counts above 1000/mm was significantly faster in the rhG-CSF treated group (3±0.72 days vs 7±0.81 days; p<0.001). The incidence of febrile neutropenia and empiric parenteral antibiotic use were lower in study patients (%36 vs %64 ; p<0.05). But there was no reduction in the incidence of documented infections. Full doses of chemotherapy could be given on time to 26/26 (%100) rhG-CSF patients but to only 18/24 (%75) controls (p<0.01). All patients tolerated cytokine treatment well. Our results showed that rhG-CSF has an important role in decreasing period of neutropenia maintaining chemotherapy schedule and allowing patients to receive full doses of chemotherapy on time. [Journal of Turgut Özal Medical Center 1998;5(1):24-29] | en_US |
| dc.identifier.citation | Özkalemkaş, F.;Ali, R.;Karaaslan, Y.;Özkocaman, V.;Tunalı, A.;Turgut Özal Tıp Merkezi Dergisi.5 (1) :1998. İnönü Üniversitesi, Malatya. | en_US |
| dc.identifier.uri | http://www.totmdergisi.org/articles/1998/volume5/issue1/1998_5_1_5.pdf | |
| dc.identifier.uri | https://hdl.handle.net/11616/2507 | |
| dc.language.iso | en | en_US |
| dc.publisher | Turgut Özal Tıp Merkezi Dergisi | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject | G-CSF | en_US |
| dc.subject | Hodgkin hastalığı | en_US |
| dc.subject | nötropeni | en_US |
| dc.subject | enfeksiyon | en_US |
| dc.title | Hodgkin hastalığının standart tedavisinde rekombinant human granülosit koloni stimüle edici faktör kullanımı | en_US |
| dc.title.alternative | Recombinant Human Granulocyte-Colony Stimulating Factor (rh G-CSF) in Standard Chemotherapy of Hodgkin’s Disease | en_US |
| dc.type | Article | en_US |
